Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.21), $0.17 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $63.57 million.

Insmed continues to expect full-year 2023 global revenues for ARIKAYCE to be between $285 million and $300 million.

For earnings history and earnings-related data on Insmed (INSM) click here.